Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 865541 | ISIN: FR0000120107 | Ticker-Symbol: BGJ
Frankfurt
21.01.25
21:49 Uhr
50,80 Euro
+0,20
+0,40 %
1-Jahres-Chart
SAVENCIA SA Chart 1 Jahr
5-Tage-Chart
SAVENCIA SA 5-Tage-Chart
RealtimeGeldBriefZeit
50,6051,8021.01.
GlobeNewswire (Europe)
149 Leser
Artikel bewerten:
(0)

SAVENCIA: 2024 half-yearly results

Finanznachrichten News

Thursday, September 19, 2024

Press Release: 2024 half-yearly results



Solid operating performances

Key figures in €M

30/06/24

% of sales

30/06/23

% of sales

% changes
TotalStructureChange &

IAS 29
Organic growth (1)
Sales3,380 3,376 0.11.9-2.60.8
- Cheese Products1,92056.81,93457.3-0.70.0-0.80.2
- Others Dairy Products1,57846.71,55246.01.74.2-4.92.4
- Unallocated -118-3.5-110-3.27.60.2-5.212.6
Current Operating Profit1103.31123.3
Operating profit1033.0982.9
Financial result-21 -15
Corporate taxes-25 -28
Result for the period641.9581.7
Net income, Group share581.7511.5
Net debt (excluding IFRS 16)438 600

First-half 2024 financial statements

Savencia Fromage & Dairy sales remain stable as of 30 June 2024 with an increase of 0.1% compared to the previous year. This includes organic growth of 0.8% driven by Other Dairy Products, a positive structural effect of 1.9% related to the integration of Williner, consolidated since April 2023, and an unfavorable currency effect of 2.6% resulting from the devaluation of the Argentine peso against the euro.

Organic sales growth of Cheese Products of 0.2% is mainly due to a favorable price effect, that offsets a contraction in volumes, notably in Europe due to a context that remains inflationary and affects consumers' purchasing power. Outside France, volumes have seen different developments depending on the region, with notably a solid growth in South America.

At constant scope and exchange rates, Other Dairy Products sales are up 2.4%, benefiting from a good momentum in international markets, which offset the decline in global quotations for industrial ingredients.

Current Operating Profit stands at €110 million. This near-stability results, on the one hand, from a recovery in the Cheese Products activity and on the other hand, from a contraction in Other Dairy Products, which have been impacted by the continued high price of milk and the decline in industrial ingredient quotations.

Net income improved by €6 million to €64 million.

Savencia Fromage & Dairy debt decreased by €162 million thanks to good control of working capital requirements.

CRS commitments

Savencia Fromage & Dairy teams remain fully committed to building and executing decarbonization trajectories in accordance with the SBTi commitments made in March 2023 and have been pursuing optimization plans across all production sites.

On the societal front, numerous initiatives are being launched in all countries. As an example, Elle & Vire has become a founding partner of the "Grand Cause Biodiversité" alongside other major French players. This cause is led by the collaborative platform Make.org which aims to support citizen initiative projects.

(1) Explanatory note: change in aggregate presentations

The definitions and methods of the organic growth and currency effect aggregates have changed with effect from 1st January 2024, as explained below. The definition of the "structure effect" aggregate has not changed. The definition is disclosed in the Group's financial report.

Since January 1st, 2024, Argentina, a country with a hyperinflationary economy, is included in the variations in organic data as follows: the growth in net turnover in this country exceeding approximately 26% per year (on average an annual inflation level of 26% over 3 years generally requires the application of hyperinflation restatement within the meaning of IFRS standards) is excluded from the calculation of net turnover growth in organic data and integrated with the impact of the hyperinflation restatement (IAS 29) and exchange rate effects

Note: 2023 items have not been restated

(The next publication will be on October 24, 2024)

Further information can be found on the website savencia-fromagedairy.com


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.